A Cautious Look at Amgen’s Denosumab

Original Article from Seeking Alpha Long Investment

Amgen (AMGN) is global biotechnology company who sells pharmaceutical drugs, including Aranesp & Epogen (anemia), Enbrel (rheumatoid arthritis), and Neulasta & Neupogen (prevent infections in chemotherapy patients).

Although there are concerns about the effectiveness and side effects of some of these drugs (notably Aranesp and Epogen),

Amgen earned $4.6 billion on $14.6 billion in sales in 2009.

Complete Story »

Read more articles from Seeking Alpha Long Investment

More Information: